Plain-English translation of NCT07282171 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new medication called given as a single injection to pregnant women hospitalized with preeclampsia—a serious condition where high blood pressure develops during pregnancy. The study wants to find the right dose and understand how safe this medication is for both mother and baby. Researchers will watch how the medication works in your body and track your health and your baby's health through delivery and beyond.
Preeclampsia is a dangerous condition that can force doctors to deliver a baby early, which carries risks for the newborn. This medication is designed to help extend pregnancy safely in women with preeclampsia, giving babies more time to develop in the womb.
You likely qualify if…
You likely don't qualify if…
You will receive a single injection of the medication under your skin on Day 1 while you are in the hospital. You'll stay hospitalized and receive close monitoring of your health and your baby's health through delivery and for 42 days after you give birth. Your baby will be followed for up to 24 months after birth, with visits to check their development and health.
AI-generated summary from trial data · Jul 7, 2026 · Not medical advice
Australia